Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Control Crohn Safe with episodic adalimumab monotherapy as first-line treatment (CoCroS)
2024-516002-33-01Phase 4Authorised
- Sponsor
- Maastricht University
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of adalimumab in Crohn's disease, sponsored by Maastricht University. Primary endpoint: Yearly-quarters of corticosteroid-free clinical and biochemical remission at week 96. Planned start Dec 2024; status: authorised.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2024-516002-33-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516002-33-01.